Table 3.

Secondary outcomes

	Verapamil (n = 47)	Beta blocker (n = 383)	No rate control (n = 236)	P-value
Composite of secondary outcome, n (%)	11 (23)	113 (30)	62 (26)	0.52
Cardiovascular death, n (%)
Cardiac	0 (0)	0 (0)	0 (0)	1
Vascular non-cardiac	1 (2)	2 (1)	1 0	0.27
Hospitalizations for arrhythmic events, n (%)	8 (17)	92 (24)	56 (24)	0.61
Heart failure, n (%)	1 (2)	7 (2)	5 (2)	0.91
Acute coronary syndrome, n (%)	0 (0)	6 (2)	3 (1)	1
Ischaemic thromboembolic complications, n (%)	1 (2)	10 (3)	1 (0)	0.1
Major bleeding, n (%)	0 (0)	9 (2)	3 (1)	0.57
Life-threatening effects of drugs, n (%)	1 (2)	2 (1)	0 (0)	0.155